
Deucravacitinib has recently been approved for the treatment of adults with active psoriatic arthritis, expanding its therapeutic role beyond plaque psoriasis. Psoriatic arthritis is a chronic, autoimmune condition associated with psoriasis of the skin or nails. It causes joint pain, stiffness, and swelling, and can lead to impaired physical function and progressive joint damage.
Deucravacitinib provides a new treatment option for patients who have had an inadequate response to, or are unable to tolerate, a prior disease-modifying antirheumatic drug (DMARD). In these patients, deucravacitinib may be used as monotherapy or in combination with a conventional synthetic DMARD.
Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor. The TYK2 enzyme is involved in inflammatory signalling pathways implicated in psoriatic arthritis and other immune-mediated diseases. While TYK2 is part of the Janus kinase (JAK) family, the selectivity of deucravacitinib distinguishes it from conventional JAK inhibitors. Its high degree of selectivity is expected to minimise off-target effects and toxicities. However, infections and viral reactivation remain recognised adverse effects.
In a recently published Phase 3 trial, deucravacitinib demonstrated superior efficacy compared with placebo. The primary endpoint, an American College of Rheumatology 20% improvement in response (ACR20), was achieved in 54.2% of patients receiving deucravacitinib compared with 39.4% of those receiving placebo at week 16. Clinical responses were evident by week 8, continued to improve through week 28, and were maintained to week 52. Higher rates of ACR50 and ACR70 responses were also observed.
The usual dose is one 6 mg tablet taken once daily with or without food. As an oral treatment, deucravacitinib may be preferred by some patients over injectable biologic therapies. However, treatment selection should also consider clinical presentation, previous treatments, comorbidities, and safety considerations.
References:
- Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024; 83(6): 760-774.
- Mease PJ, Chandran V, Armstrong AW, Blanco R, Ogdie A, Siegel EL, et al. Deucravacitinib in active psoriatic arthritis: efficacy and safety up to 52 weeks from the randomized, double-blind, phase 3 POETYK PsA-2 trial. Arthritis Rheumatol. 2026. doi: 10.1002/art.70280. Online ahead of print.
- Sotyktu™ (Deucravacitinib) Australian approved product information. Mulgrave: Bristol-Myers Squibb Australia. Approved September 2026.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates
